(TXMD) TherapeuticsMD, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TXMD) TherapeuticsMD, Inc. Complete Analysis Pack
TherapeuticsMD Business Model Canvas: Fast, Actionable Insight
Unlock the full Business Model Canvas for TherapeuticsMD, Inc. and see how its value proposition, partnerships, and revenue logic fit together. This concise, company-specific breakdown is ideal for investors, analysts, and strategists who want actionable insight fast. Download the full canvas to go beyond the preview and sharpen your research.
Partnerships
Wholesale pharmacy distributors
TherapeuticsMD reached pharmacies through wholesale pharmacy distributors, the same network that moves about 95% of U.S. prescription drugs and keeps national availability broad. This mattered for Prenate prenatal vitamins and prescription products because the channel can place inventory into tens of thousands of pharmacies fast.
Retail pharmacy distributors
Retail pharmacy distributors are the last-mile link for TherapeuticsMD, Inc., and U.S. retail pharmacies fill about 90% of prescriptions. That access is critical for IMVEXXY, BIJUVA, and ANNOVERA, while pharmacy shelves also help vitamin brands reach shoppers where they already buy medicines.
Prescribing healthcare professionals
OB-GYNs and other prescribers are TherapeuticsMD, Inc.'s key external partners because they diagnose, start therapy, and keep patients on treatment. In women’s health, that matters most for hormone therapy and contraception, where repeat prescribing drives steady use and revenue.
Clinical development partners
TherapeuticsMD, Inc. relies on clinical development partners to advance 5 preclinical candidates, TX-005HR through TX-009HR, from research support into later-stage testing. This setup lowers internal load and helps build pipeline value by moving compounds toward Phase 1 and Phase 2 faster.
- 5 preclinical candidates need outside R&D support
- Partners help reach later-stage trials
- Pipeline value depends on this base
Manufacturing and logistics partners
TherapeuticsMD, Inc. depends on contract manufacturers and logistics partners to keep marketed medicines and prenatal vitamins moving, with backup capacity, packaging control, and on-time shipment as core safeguards. In 2025, U.S. drug shortages were still near record levels, with 270 active shortages reported by ASHP, so supply continuity is a direct operating risk.
- Supports steady production.
- Maintains quality and packaging.
- Keeps shipments and supply flowing.
TherapeuticsMD’s Pharmacy Network Drives U.S. Prescription Reach
TherapeuticsMD, Inc. depends on wholesale and retail pharmacy partners to move IMVEXXY, BIJUVA, ANNOVERA, and Prenate into the U.S. prescription channel, which fills about 90% of prescriptions and reaches nearly all pharmacies through distributors handling about 95% of drug volume. OB-GYNs and other prescribers stay central because they start and renew women’s health therapy.
| Partner | Why it matters | Key data |
|---|---|---|
| Pharmacy distributors | National reach | 95% of U.S. drug volume |
| Retail pharmacies | Last-mile access | 90% of prescriptions |
| Manufacturers/logistics | Supply continuity | 270 U.S. shortages in 2025 |
What is included in the product
Detailed Word Document
A concise Business Model Canvas mapping TherapeuticsMD’s women’s health strategy, customer segments, value proposition, and key risks.
Customizable Excel Spreadsheet
Quickly shows how TherapeuticsMD reduces patient pain with a clear, one-page business model snapshot.
Reference Sources
Provides a credible source trail for TherapeuticsMD, Inc. that helps validate key claims and supports faster, better decisions.
Activities
Commercializing IMVEXXY, BIJUVA, and ANNOVERA
TherapeuticsMD’s main activity is commercializing three branded women’s health products: IMVEXXY, BIJUVA, and ANNOVERA. That means educating physicians, managing payer access, and keeping pharmacy fulfillment smooth across 3 distinct therapies for vaginal, menopausal, and contraceptive needs.
Advancing five preclinical candidates
TherapeuticsMD, Inc. is advancing five preclinical candidates, TX-005HR, TX-006HR, TX-007HR, TX-008HR, and TX-009HR, to expand its women’s health pipeline. Work centers on new hormone-based formulations and delivery forms, with five programs aimed at broadening future treatment options.
Producing prenatal vitamin lines
TherapeuticsMD, Inc. makes and sells branded and generic prescription prenatal vitamins through 4 labels: vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1. This line expands the business beyond prescription therapeutics and adds a second revenue stream tied to maternal health.
Managing regulatory and quality compliance
TherapeuticsMD, Inc. must keep prescription-drug compliance tight because FDA oversight does not stop after approval; it covers quality systems, labeling, and safety monitoring. After reporting $0 product revenue in 2024 following its portfolio divestiture, the company still depends on clean regulatory records and product credibility to protect market access.
One missed label change or safety signal can trigger delays, recalls, or enforcement, so this activity stays core to the model.
- Keep FDA filings and updates current
- Track safety signals and adverse events
- Control labeling and quality records
Supporting pharmacy and provider demand generation
TherapeuticsMD, Inc. relies on educating prescribers and pharmacy channels, because demand generation turns awareness into new prescriptions and repeat refills. In women’s health, where therapy choice often starts with provider trust and pharmacy access, this activity directly supports script conversion and persistence.
Latest company filings show this channel-led model is still central to revenue capture, since every incremental prescriber touch can lift fill rates and refill retention.
- Educate prescribers first
- Convert awareness into scripts
- Support refill persistence
- Strengthen pharmacy pull-through
TherapeuticsMD: Women’s-Health Focus, 3 Products, 5 Pipeline Programs
TherapeuticsMD, Inc. now focuses on branded women’s-health commercialization, with 3 marketed products and 4 prenatal-vitamin brands, while also advancing 5 preclinical hormone programs. After portfolio divestiture, 2024 product revenue was $0, so its key work is FDA compliance, prescriber education, payer access, and pharmacy pull-through.
| Activity | Data |
|---|---|
| Marketed products | 3 |
| Preclinical programs | 5 |
| 2024 product revenue | $0 |
Preview Before You Purchase
Business Model Canvas
The TherapeuticsMD, Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It is not a mockup or sample—it’s a direct snapshot of the final file.
Once you complete your order, you’ll unlock the same fully formatted document, ready for editing, presenting, or sharing. What you see is what you get, with no hidden changes or missing sections.
Resources
Three marketed prescription brands
TherapeuticsMD’s key resources are its three marketed prescription brands: IMVEXXY, BIJUVA, and ANNOVERA. Together, they anchor the Company Name’s commercial footprint in women’s health and are the core assets behind its brand recognition and revenue base.
Five preclinical pipeline assets
TherapeuticsMD, Inc. has five preclinical pipeline assets, TX-005HR through TX-009HR, which give it a broader development base beyond current products. The mix includes creams, patches, and an oral formulation, so the company can test multiple delivery formats for future growth.
Prenatal vitamin brand portfolio
TherapeuticsMD, Inc.'s prenatal vitamin brand portfolio spans four labels vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 and now supports two product platforms. This mix helps drive recurring prescription and distribution activity, while broadening the resource base beyond a single brand line.
Women’s health formulation expertise
TherapeuticsMD, Inc.'s women’s health formulation expertise centers on 3 areas: hormone therapy, contraception, and prenatal nutrition. This intangible know-how shapes product design and positioning, helping the company decide which formulations fit unmet needs in women’s health.
- 3 focus areas: hormone therapy, contraception, prenatal nutrition
- Core intangible resource for product development
- Supports sharper market positioning
Boca Raton, Florida headquarters
TherapeuticsMD’s Boca Raton, Florida headquarters centralizes leadership and administrative work, so decisions on development, commercialization, and compliance stay aligned. It also acts as the control point for governance and reporting across the Company’s core functions.
- Boca Raton, Florida: corporate HQ
- Hosts leadership and admin teams
- Supports cross-functional coordination
3 brands, 5 assets, 4 labels: Company Name’s women’s health engine
Company Name’s key resources are 3 marketed brands, 5 preclinical pipeline assets, and 4 prenatal vitamin labels. Its 3 focus areas—hormone therapy, contraception, and prenatal nutrition—plus Boca Raton HQ support product design, commercialization, and governance.
| Resource | Count |
|---|---|
| Marketed brands | 3 |
| Preclinical assets | 5 |
| Prenatal labels | 4 |
| Core focus areas | 3 |
Value Propositions
Women’s health specialization
TherapeuticsMD built its brand around women’s health, with a focused portfolio of 3 FDA-approved products in menopause and contraception. That narrow therapeutic identity lets the Company concentrate capital and R&D on conditions that affect women across life stages, instead of spreading resources across many disease areas.
Moderate to severe dyspareunia treatment
IMVEXXY is prescribed for moderate to severe dyspareunia, a core symptom of postmenopausal vulvovaginal atrophy, which affects many women after menopause. By targeting this specific pain burden, TherapeuticsMD gives patients a low-dose local estrogen option and gives prescribers a focused treatment for a high-need condition.
Bio-identical hormone therapy option
BIJUVA combines 1 mg 17β-estradiol and 100 mg progesterone in a single oral capsule, giving eligible women a bio-identical hormone therapy option. It is FDA-approved to treat moderate to severe vasomotor symptoms, which affect about 75% of menopausal women.
Innovative contraception delivery
ANNOVERA is a reusable vaginal ring that delivers contraception for 13 cycles over 1 year, giving TherapeuticsMD, Inc. a non-oral, branded option in reproductive health. As the first and only reusable hormonal contraceptive ring in the U.S., it helps differentiate the Company with a delivery format that fits women who want to avoid daily pills.
- 13 cycles, 1 year of use
- Non-oral, branded contraception
- First reusable U.S. contraceptive ring
Prenatal vitamin product range
TherapeuticsMD’s prenatal vitamin range adds a non-therapeutic income stream: prescription prenatal products, plus branded and generic labels, broaden access for pregnancy nutrition needs. This matters in a market where women need folic acid, iron, and DHA support across pregnancy, and the category can stay relevant beyond episodic treatment use.
- Prescription prenatal vitamins widen reach.
- Branded and generic labels lift access.
- Supports pregnancy nutrition demand.
TherapeuticsMD: Women’s Health Niche With 3 FDA-Approved Brands
TherapeuticsMD, Inc. focuses on women’s health with 3 FDA-approved brands: IMVEXXY for dyspareunia, BIJUVA for menopausal hot flashes, and ANNOVERA, the first reusable U.S. vaginal contraceptive ring. That mix gives the Company a narrow, high-need niche across menopause and reproductive care.
| Asset | Value prop |
|---|---|
| IMVEXXY | Local estrogen |
| BIJUVA | 1 mg/100 mg oral HT |
| ANNOVERA | 13 cycles, 1 year |
Customer Relationships
Prescription-driven provider relationship
TherapeuticsMD, Inc.’s customer relationship starts with a healthcare professional’s prescription, then shifts to pharmacy dispensing, so the prescriber drives demand. In FY2025, the company had no material continuing product revenue after its asset sales, which underscores how dependent this model is on provider adoption and pharmacy access.
HCP education and support
TherapeuticsMD must educate prescribers on indications and use for its 3 branded women’s health therapies, so HCP support directly shapes adoption. Clear product education helps explain differentiation and can lift prescribing of branded options in a category where misuse or confusion can slow uptake.
This relationship works best when clinical guidance and access support are easy to use, because women’s health decisions often depend on the right fit for the patient and the prescriber’s confidence in the therapy.
Pharmacy-based fulfillment
Pharmacy-based fulfillment is TherapeuticsMD, Inc.’s main prescription channel, so patients can get products and refills through roughly 60,000 U.S. retail pharmacies, which helps convenience and continuity. It also gives TherapeuticsMD, Inc. direct exposure to dispensing behavior, where fill rates and substitution choices can shape product access.
Medical information and safety monitoring
TherapeuticsMD, Inc. builds this relationship on ongoing safety communication: patients and prescribers need quick answers on product use, side effects, and tolerability. Pharmacovigilance is core, because prescription drugs must track and escalate adverse events in real time; FDA postmarketing safety systems still process thousands of reports each year.
- Medical support answers tolerability questions.
- Safety monitoring tracks adverse events.
- Pharmacovigilance keeps the relationship compliant.
Brand loyalty across life stages
TherapeuticsMD, Inc.'s women’s-health portfolio spans menopause, contraception, and prenatal use, so one brand can stay relevant across multiple life stages and support repeat engagement over time. That continuity helps build long-term brand awareness and trust, especially in a market where women may move from prenatal care to contraception and then menopause support.
- Repeat use across life stages
- Supports brand continuity
- Builds long-term awareness
TherapeuticsMD’s Revenue Hinges on Prescribers and Pharmacy Access
TherapeuticsMD, Inc. customer relationships are HCP-led and pharmacy-filled, so prescriber trust and access drive demand. In FY2025, the company reported no material continuing product revenue after asset sales, which makes this channel highly dependent on physician adoption and dispensing access.
Safety support and product education matter most, because women’s health therapy use depends on clear dosing, side-effect guidance, and compliant pharmacovigilance.
| Metric | FY2025 |
|---|---|
| Continuing product revenue | None material |
| Primary channel | Prescription + pharmacy |
Channels
Wholesale pharmacy distributors
Wholesale pharmacy distributors are a core route to market for TherapeuticsMD, Inc., moving products from the manufacturer into pharmacy networks and helping extend reach across regions. This channel matters because it lowers last-mile friction and supports broad access where local pharmacy coverage is fragmented.
Retail pharmacy distributors
Retail pharmacy distributors are the main path from prescription to fill for TherapeuticsMD, Inc., because they place branded products where patients actually pick up meds. This channel matters for script-to-sale conversion: in U.S. retail pharmacies, about 90% of prescriptions are dispensed, so shelf access directly affects volume and refill capture.
Prescribing clinicians
OB-GYNs and other clinicians are the main gatekeepers for TherapeuticsMD, Inc. because demand starts when they prescribe, so their offices are the key access point for treatment. In a prescription-only model, clinician trust and office workflow drive who gets started and stays on therapy.
Pharmacy dispensing network
TherapeuticsMD, Inc. relies on the pharmacy dispensing network as the last transactional step, where dispensing pharmacies fill prescriptions, manage refills, and keep patients on therapy. In the U.S., retail pharmacies process billions of prescription claims each year, so this channel directly affects access, adherence, and revenue conversion.
- Completes the prescription journey
- Supports refills and adherence
- Drives patient access at scale
Branded product information
Branded product information is the channel TherapeuticsMD, Inc. uses to explain how its prescription products work, who they are for, and how to use them safely. In pharma, this channel supports awareness and use by sharing FDA-approved indications, dosing, and warnings; for BIJUVA and ANNOVERA, clear label and HCP materials are part of the commercial model.
- Drives prescriber awareness
- Explains benefits and use
- Shares approved safety details
TherapeuticsMD’s Rx Pipeline Runs Through Retail Pharmacies
TherapeuticsMD, Inc. depends on prescribers, wholesale distributors, and retail pharmacies to move a script from office visit to fill. The channel mix is built for prescription access, refill capture, and label-driven demand, with retail pharmacies still dispensing about 90% of U.S. prescriptions.
| Channel | Role | Key data |
|---|---|---|
| Retail pharmacies | Fill and refill | ~90% of U.S. Rx |
Customer Segments
Postmenopausal women with dyspareunia
This segment matches the IMVEXXY indication: postmenopausal women with dyspareunia, or painful intercourse tied to menopause. In the U.S., about 51 million women are postmenopausal, and dyspareunia is a core symptom of genitourinary syndrome of menopause, so this is TherapeuticsMD, Inc.'s key therapeutic audience.
Postmenopausal women with vasomotor symptoms
Postmenopausal women with vasomotor symptoms are BIJUVA’s core users: women with moderate to severe hot flashes and night sweats who need hormone therapy. Vasomotor symptoms can last 7 to 10 years, so this segment supports recurring, symptom-driven demand for a prescription option.
Women seeking contraception
ANNOVERA serves women who need birth control, especially those who want a non-oral option; the FDA-approved vaginal ring works for up to 1 year with 1 ring, 1 cycle. In the U.S., about 62 million women are age 15-44, and this segment values convenience, adherence, and proven efficacy.
Pregnant women needing prenatal vitamins
Pregnant women needing prenatal vitamins are a clear fit for TherapeuticsMD, Inc. because the vitamin portfolio is built for prenatal nutrition and pregnancy-related supplementation, widening the Company Name’s reach beyond menopause and contraception. The U.S. had about 3.6 million births in 2024, so this is a large, recurring need tied to maternal care.
Prenatal nutrition need, not one-time use
Supports pregnancy-related supplementation
Expands beyond menopause and contraception
OB-GYNs and other prescribers
OB-GYNs and other prescribers are the gatekeepers in prescription drugs: they choose the product, start therapy, and shape continuation. In women’s health, this is the key demand engine, so TherapeuticsMD must win clinical trust at the point of care, where one prescriber can affect many patient starts in 2025-2026.
- Drive treatment initiation
- Shape refill and persistence
- Influence most women’s-health demand
- Need strong clinical evidence
TherapeuticsMD Targets Huge, Recurring Women's Health Markets
TherapeuticsMD, Inc. serves four core customer groups: postmenopausal women with dyspareunia or vasomotor symptoms, women seeking a long-acting non-oral contraceptive, pregnant women needing prenatal vitamins, and OB-GYNs who choose and renew therapy. Its biggest demand pools are large and recurring, with about 51 million U.S. postmenopausal women, 62 million women ages 15-44, and 3.6 million U.S. births in 2024.
| Segment | Need | Size |
|---|---|---|
| Menopause | IMVEXXY, BIJUVA | 51M women |
| Contraception | ANNOVERA | 62M women 15-44 |
| Prenatal | Vitamins | 3.6M births 2024 |
Cost Structure
Research and development spending
Research and development spending is a heavy cost driver for TherapeuticsMD, Inc. because its preclinical pipeline spans five programs: TX-005HR, TX-006HR, TX-007HR, TX-008HR, and TX-009HR. Each one needs formulation work, testing, and study support, so cash burn stays tied to development milestones rather than sales.
In its last active reporting cycle, TherapeuticsMD, Inc. flagged R&D as one of the largest operating uses of cash, with pipeline programs still requiring ongoing spend before any revenue can offset it.
Commercialization and marketing expenses
Commercialization and marketing expenses are a recurring operating cost for TherapeuticsMD, Inc., because IMVEXXY, BIJUVA, and ANNOVERA need sales calls, physician education, and payer access support. In the latest reported period, selling, general and administrative spending remained the main cost bucket, showing that brand support still drives cash use.
Manufacturing and supply chain costs
Manufacturing and supply chain costs for TherapeuticsMD, Inc. stay tied to producing and moving regulated pharma products and prenatal vitamins, where packaging, freight, and inventory control all add cost. In the latest public filings, product revenue was $0, so the cost base has been pared back and reliable third-party supply matters more than scale.
Regulatory and quality compliance costs
Prescription drug operations need постоянный oversight, so TherapeuticsMD, Inc. must fund quality assurance, labeling checks, and safety monitoring even after approval. These compliance costs protect market access and reduce recall or warning-letter risk; for prescription drugs, they are fixed operating costs, not optional spend.
- QA and label review
- Safety monitoring systems
- FDA compliance oversight
General and administrative expenses
TherapeuticsMD, Inc. keeps general and administrative expenses as fixed corporate overhead from its Boca Raton headquarters. Recent filings show these costs fund staffing, finance, legal, and admin systems, so they support the business platform even when revenue is low.
Boca Raton HQ drives overhead
Finance, legal, HR, admin are fixed costs
G&A supports the operating platform
TherapeuticsMD Burns Cash Without Revenue
TherapeuticsMD, Inc. cost structure is driven by five pipeline programs, ongoing FDA and quality work, and fixed headquarters overhead in Boca Raton. Product revenue was $0, so R&D, SG&A, and compliance costs still shape cash burn more than scale economics.
| Cost item | Data point |
|---|---|
| Pipeline | 5 programs |
| Product revenue | $0 |
| Fixed overhead | Boca Raton HQ |
Revenue Streams
IMVEXXY prescription sales
IMVEXXY is a marketed prescription vaginal estradiol product, so TherapeuticsMD, Inc. earns direct pharma revenue only after a physician writes the script and a pharmacy dispenses it. That makes sales dependent on prescription volume, refill rates, and payer access, not on direct-to-consumer selling.
BIJUVA prescription sales
BIJUVA prescription sales support TherapeuticsMD, Inc. revenue through recurring hormone therapy demand for moderate to severe vasomotor symptoms. In 2025 filings, ongoing dispensing kept BIJUVA as a repeat-fill product, which helps stabilize sales versus one-time purchases.
ANNOVERA prescription sales
ANNOVERA prescription sales create a contraceptive revenue stream for TherapeuticsMD, Inc., with each vaginal ring designed for 13 cycles over 1 year. The product’s once-yearly ring format sets it apart in reproductive health and supports prescription-based revenue tied to women’s contraceptive demand.
Prenatal vitamin product sales
Prenatal vitamin product sales are a non-hormone revenue stream for TherapeuticsMD, Inc., led by vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1. This mix helps diversify income beyond hormone products, but the segment has been small versus the company’s legacy business.
- Brands: vitaTrue, vitaPearl, vitaMedMD, BocaGreenMD Prena1
- Revenue type: non-hormone prenatal vitamins
- Benefit: wider income mix
Wholesale and retail distribution receipts
TherapeuticsMD, Inc. sells through wholesale and retail pharmacy distributors, so those channels turn shipped product into recognized revenue and widen access. In its latest reported filings, the company has been operating with no reported product sales revenue, so any future volume from distributor reach would be the key driver of this stream.
- Wholesale and retail pharmacies convert shipments into revenue
- Distribution reach supports market access and volume
- Latest filings show no reported product sales revenue
TherapeuticsMD Revenue Hinges on Prescription Rebound
TherapeuticsMD, Inc. revenue streams come mainly from prescription fills of IMVEXXY, BIJUVA, and ANNOVERA, plus smaller prenatal vitamin sales, all routed through pharmacies and distributors. In the latest reported 2025 filing, product sales revenue was $0, so near-term revenue depends on a return in prescription volume and payer access.
| Stream | 2025 status |
|---|---|
| Prescription drugs | IMVEXXY, BIJUVA, ANNOVERA |
| Prenatal vitamins | vitaTrue, vitaPearl, vitaMedMD, BocaGreenMD Prena1 |
| Product sales revenue | $0 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.